Valuation
Medical DevicesLive · Yahoo FinancePrice
$76.62
52-Week Range
Decision Context
Outperforms sector peers on capital efficiency. The peer comparison edge is a meaningful differentiator in the current competitive landscape.
Based on filing period ending Mar 2026
FisclearScore is a quantitative model using public financial data and sector median benchmarks (refreshed monthly). Not financial advice. Always conduct independent due diligence.
Macro Context
SWOT Analysis — DXCM
Inflationary BoomStrengths
EPS (Diluted): $2.09 (+47.2% YoY) — Earnings per share rose 47% — each share earned more.
Operating Cash Flow: $1.4B (+45.6% YoY) — Operating cash flow grew 46% — the business generated more cash from day-to-day operations.
Net Income: $836.3M (+45.1% YoY) — Profit grew 45% — the company kept more of each dollar earned.
Revenue: $221.0M (+29.1% YoY) — Revenue grew 29% — the company sold more goods or services than the prior year.
Gross Profit: $2.8B (+14.9% YoY) — Gross profit rose 15% — the spread between revenue and direct costs improved.
Weaknesses
R&D spending is 271% of revenue — heavy investment in future growth, but also a drag on current profitability.
Opportunities
No clear opportunities identified at this time.
Threats
Gross margin compressed by 156.4pp — input costs or pricing pressure is eroding profitability on each dollar of revenue.
Financial Charts
Revenue vs Net Income
Gross Profit vs Operating Income
Margin Trend
Operating Cash Flow
Year-over-Year Changes
EPS (Diluted)
$2.09
was $1.42
Earnings per share rose 47% — each share earned more.
Operating Cash Flow
$1.4B
was $989.5M
Operating cash flow grew 46% — the business generated more cash from day-to-day operations.
Net Income
$836.3M
was $576.2M
Profit grew 45% — the company kept more of each dollar earned.
Revenue
$221.0M
was $171.2M
Revenue grew 29% — the company sold more goods or services than the prior year.
Gross Profit
$2.8B
was $2.4B
Gross profit rose 15% — the spread between revenue and direct costs improved.
Risk Flags
0 high · 1 medium · 1 low- ◈ Medium
Gross margin compressed by 156.4pp — input costs or pricing pressure is eroding profitability on each dollar of revenue.
- ○ Low
R&D spending is 271% of revenue — heavy investment in future growth, but also a drag on current profitability.
Price History
Technical Signals
Daily closes · 1-year dataLatest News
via FinnhubGet the weekly digest
5 company reports + macro context every week, free. No spam.
- Unlimited goal simulations
- 5 free company report summaries per day
- Weekly financial insights newsletter
External Links
Trade DXCM
Links open broker research pages. Not an endorsement or recommendation.
Research DEXCOM, INC.
Data sourced from SEC EDGAR, FRED (Federal Reserve Economic Data), and Yahoo Finance. For informational purposes only. Not financial advice.